TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 04/02/21

I am a big fan of the ARK funds and Cathie Wood in particular. Upon reviewing the asset mix of the ARK Genomic Revolution Multi-Sector ETF, I came away less than enthused. The turbocharged returns seem to be a thing of the past as detailed below. For further details see: ...

Takeda is a Japanese healthcare company that pays consistent dividends. The company is trying to achieve growth using acquisition and research, and so far fails. The company is not consistent enough to be a good income investment. For further details see: Takeda Is A Med...

Ionis Pharmaceuticals is at a crossroads. The pipeline begins to take form with a recent setback creating a waterfall dive in the share price. Let's examine the case for Ionis to see if the move is justified. For further details see: Ionis Pharmaceuticals: Recent Setback...

Glenview Capital Management’s 13F portfolio value increased from $3.19B to $4.36B this quarter. The number of positions increased from 45 to 54. They increased Lyft Inc. & Boston Scientific while reducing Meritor and Hologic during the quarter. The top three stakes are ...

John Paulson’s 13F portfolio value increased from $3.21B to $3.85B this quarter. Paulson & Company's largest three positions are Horizon Therapeutics, Bausch Health, and BrightSphere Investment Group. The stake in Barrick Gold was more than doubled during the quarter. ...

Prometheus Biosciences has filed to raise $125 million in a U.S IPO. The firm is developing treatments for inflammatory bowel disease conditions. RXDX is in Phase 1 safety trials for its lead candidate for the treatment of ulcerative colitis and Crohn's disease. For further ...

The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with this event. For further details see: Takeda Pharmaceutical (TAK) Presents At World Conference on Lung Cancer - Slideshow

Takeda Pharmaceutical Co Ltd (TAK) Q3 2021 Earnings Conference Call February 04, 2021, 06:00 ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development and Director Constantine...

The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2020 Q4 earnings call. For further details see: Takeda Pharmaceutical Company Limited 2020 Q4 - Results - Earnings Call Presentation

I recommended OVID for OV935 but disliked OV101. In December, OVID fell drastically after OV101's failure. OV935 thesis still stands, however, the numbers are now different. This article was written after some asked for my current opinion on the stock. For further details se...